Registry of Lobbyists
Version 4 of 45 (2006-10-31 to 2007-05-30) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Corporation: |
MERCK FROSST CANADA LTD.
16711 TransCanada Highway Kirkland, QC H9H 3L1 Canada |
| Telephone number: | 514-428-2638 |
| Fax number: | 514-428-2662 |
| Responsible officer name and position during the period of this registration: | DAWN GRAHAM, EXECUTIVE DIRECTOR, CORPORATE AFFAIRS |
| Description of activities: | At Merck Frosst, patients come first. Merck Frosst Canada Ltd. is a research-driven pharmaceutical company. Merck Frosst discovers, develops and markets a broad range of innovative medicines to improve human health. The Merck Frosst Centre for Therapeutic Research, one of the largest biomedical research facilities in Canada, has the mandate to discover new therapies for the treatment of respiratory diseases, inflammatory diseases, diabetes and osteoporosis. Merck Frosst is one of the top 20 R&D investors in Canada, with an investment of $117 million in 2004. The Company is committed to fostering partnerships to deliver the most valuable health outcomes for Canadian patients. Merck Frosst is a recognized leader in the treatment of asthma, osteoporosis, HIV/AIDS, glaucoma, prostate disease, migraines and infectious diseases. The Company also markets an extensive line of cardiovascular products for high blood pressure, elevated cholesterol and heart failure as well as a broad range of vaccines. Based in Montréal, Quebec, Merck Frosst employs nearly 1,600 people including more than 300 of the world's leading scientific personnel. It is also firmly committed to science education and sponsors a number of programs designed to spark young people's interest in science. More information about Merck Frosst is available at http://www.merckfrosst.com |
| The client is a subsidiary of the following parent companies: |
MERCK FROSST COMPANY
1959 Upper Water Street Suite 900 Halifax, NS Canada B3J 2X2 |
| Coalition | The corporation is not a member of a coalition. |
| Subsidiary: | The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking. |
| Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Name: | François Bertrand |
| Position title: | Executive Director, Medical Research |
| Public offices held: | No |
| Name: | Christian Blouin |
| Position title: | Director, Public Health |
| Public offices held: | No |
| Name: | Denis Drolet |
| Position title: | Government Affairs, Manager |
| Public offices held: | No |
| Name: | Richard Garant |
| Position title: | Executive Director, Customer Partnering Unit, East |
| Public offices held: | No |
| Name: | Mark Gibson |
| Position title: | Manager, Policy Planning |
| Public offices held: | No |
| Name: | Bernard Houde |
| Position title: | Vice President, Strategic Planning, Stakeholders & Corporate Counsel |
| Public offices held: | No |
| Name: | Louis Lamarche |
| Position title: | Manager - Public Health Affairs |
| Public offices held: | No |
| Name: | Robert Livingston |
| Position title: | Federal Government Affairs Director |
| Public offices held: | No |
| Name: | Pierre MacNeil |
| Position title: | Director, Government Relations |
| Public offices held: | No |
| Name: | Denis Rousseau |
| Position title: | Manager - Government Relations - Quebec |
| Public offices held: | No |
| Name: | Gregg Szabo |
| Position title: | Executive Director, Corporate Affairs |
| Public offices held: | No |
| Name: | Leo Van Dijk |
| Position title: | Manager, Corporate Affairs, Eastern Canada |
| Public offices held: | No |
| Name: | Sandra Wainwright |
| Position title: | Director - Regulatory Affairs |
| Public offices held: | No |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Federal Office of Regional Development – Quebec (FORD[Q]), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, Justice Canada (JC), National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Procurement Review Board of Canada (PRB), Public Health Agency of Canada (PHAC), Solicitor General Canada (SGC) | ||||||||||
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format | ||||||||||
| Subject Matter: Areas of Concern: | Constitutional Issues, Health, Industry, Intellectual Property, Internal Trade, International Relations, International Trade, Justice and Law Enforcement, Science and Technology | ||||||||||
| Subject Matter: Retrospective: | Communication with public office holders in relation to: changes to patent legislation and regulations (generally) discussions regarding the National Pharmaceuticals Strategy; health policies (generally) and vaccines; discussions regarding particularly the National Immunization Strategy, the improvement of the procurement system for vaccines in Canada, to promote the value of the pharmaceutical industry for the country's economic health and well-being of its citizens and discussions on cross-border trade. | ||||||||||
| Subject Matter: Prospective: | Communication with public office holders in relation to: changes to patent legislation and regulations (generally); discussions regarding the National Pharmaceuticals Strategy; health policies (generally) and vaccines, discussions regarding particularly the National Immunization Strategy and the improvement of the procurement system for vaccines in Canada, to promote the value of the pharmaceutical industry for the country's economic health and well-being of its citizens and discussions on cross-border trade. In addition, Merck will work to make the drug approval process more efficient. | ||||||||||
Details Regarding the Identified Subject Matter
|
|||||||||||